CA2644642C - A process for concentration of a polypeptide - Google Patents

A process for concentration of a polypeptide Download PDF

Info

Publication number
CA2644642C
CA2644642C CA2644642A CA2644642A CA2644642C CA 2644642 C CA2644642 C CA 2644642C CA 2644642 A CA2644642 A CA 2644642A CA 2644642 A CA2644642 A CA 2644642A CA 2644642 C CA2644642 C CA 2644642C
Authority
CA
Canada
Prior art keywords
composition
polypeptide
colour
interest
clarity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2644642A
Other languages
English (en)
French (fr)
Other versions
CA2644642A1 (en
Inventor
Stefan Nilsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Zymenex AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymenex AS filed Critical Zymenex AS
Priority to CA2882501A priority Critical patent/CA2882501C/en
Publication of CA2644642A1 publication Critical patent/CA2644642A1/en
Application granted granted Critical
Publication of CA2644642C publication Critical patent/CA2644642C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1085—Transferases (2.) transferring alkyl or aryl groups other than methyl groups (2.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01061—Hydroxymethylbilane synthase (2.5.1.61)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06001—Arylsulfatase (3.1.6.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01024—Alpha-mannosidase (3.2.1.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01046—Galactosylceramidase (3.2.1.46)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Water Supply & Treatment (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA2644642A 2006-04-04 2007-04-04 A process for concentration of a polypeptide Active CA2644642C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2882501A CA2882501C (en) 2006-04-04 2007-04-04 Compositions comprising alpha mannosidase and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200600488 2006-04-04
DKPA200600488 2006-04-04
DKPA200600922 2006-07-05
DKPA200600922 2006-07-05
CA2632528A CA2632528C (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2632528A Division CA2632528C (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2882501A Division CA2882501C (en) 2006-04-04 2007-04-04 Compositions comprising alpha mannosidase and uses thereof

Publications (2)

Publication Number Publication Date
CA2644642A1 CA2644642A1 (en) 2007-10-11
CA2644642C true CA2644642C (en) 2016-01-26

Family

ID=38472949

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2644642A Active CA2644642C (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
CA2632528A Active CA2632528C (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
CA2882501A Active CA2882501C (en) 2006-04-04 2007-04-04 Compositions comprising alpha mannosidase and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2632528A Active CA2632528C (en) 2006-04-04 2007-04-04 A process for concentration of a polypeptide
CA2882501A Active CA2882501C (en) 2006-04-04 2007-04-04 Compositions comprising alpha mannosidase and uses thereof

Country Status (20)

Country Link
US (6) US20090246187A1 (https=)
EP (4) EP2628746B1 (https=)
JP (6) JP2009532394A (https=)
KR (3) KR101504969B1 (https=)
CN (1) CN105233276A (https=)
AU (2) AU2007234195B2 (https=)
BR (1) BRPI0709737A2 (https=)
CA (3) CA2644642C (https=)
DK (1) DK2628746T3 (https=)
ES (3) ES2928096T3 (https=)
HU (1) HUE042402T2 (https=)
IL (4) IL194267A (https=)
MX (1) MX2008012748A (https=)
NO (3) NO347673B1 (https=)
NZ (7) NZ607595A (https=)
PL (3) PL2631242T3 (https=)
PT (1) PT2628746T (https=)
SI (1) SI2628746T1 (https=)
WO (1) WO2007112757A2 (https=)
ZA (2) ZA200805346B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1713904B1 (en) 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
HUE042402T2 (hu) * 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére
CA2790786C (en) * 2010-02-24 2019-09-24 Zymenex A/S Process for production and purification of recombinant lysosomal alpha-mannosidase
LT2588130T (lt) * 2010-06-25 2016-12-12 Shire Human Genetic Therapies, Inc. Terapinės priemonės pristatymas cns
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
HRP20191923T1 (hr) * 2010-06-25 2020-01-10 Shire Human Genetic Therapies, Inc. Postupci i sastavi za isporuku arilsulfataze a u cns
PT3103469T (pt) 2010-06-25 2021-03-04 Shire Human Genetic Therapies Administração de agentes terapêuticos no snc
US10336992B2 (en) 2011-07-08 2019-07-02 Shire Human Genetic Therapies, Inc. Methods for purification of arylsulfatase A
US20140377244A1 (en) 2011-12-23 2014-12-25 Shire Human Genetic Therapies, Inc. Stable formulations for cns delivery of arylsulfatase a
NZ707753A (en) * 2012-11-13 2019-07-26 Chiesi Farm Spa Purification of recombinant human galactocerebroside β-galactosidase (rhgalc)
CA2893609A1 (en) * 2012-12-11 2014-06-19 Centogene Ag Method for the diagnosis of metachromatic leukodystrophy
CN112126634A (zh) 2013-01-09 2020-12-25 夏尔人类遗传性治疗公司 含用于纯化芳基硫酸酯酶a的方法
WO2014144549A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Factor ix polypeptide formulations
AU2015236340B2 (en) * 2014-03-24 2020-02-06 Bioverativ Therapeutics Inc. Lyophilized factor IX formulations
EP3676375A4 (en) * 2017-08-31 2021-04-07 Green Cross Corporation PROCESS FOR PURIFYING A SULFATASE PROTEIN
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2041280A1 (en) 1990-05-10 1991-11-11 Yosuke Sawada Arylsulfatase
NO960163D0 (no) * 1996-01-15 1996-01-15 Thomas Berg Mutasjonsdeteksjon av bovin
DE69901536T2 (de) 1998-01-27 2003-01-16 Hemebiotech A/S, Hellerod Behandlung von akuter intermittierender porphyria oder anderen porphyrischen krankheiten
IL140155A (en) * 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
DK2270044T3 (en) * 1998-06-09 2015-01-26 Csl Behring Ag Liquid immunoglobulin G (IgG) product
US6537777B1 (en) 1998-07-27 2003-03-25 Hemebiotech A/S Human porphobilinogen deaminase sequences
AUPQ026799A0 (en) * 1999-05-10 1999-06-03 Csl Limited Method of increasing protein stability by removing immunoglobulin aggregates
JP2003505057A (ja) 1999-07-27 2003-02-12 ヘム−バイオテック エイ／エス ｒｈＰＢＧＤの製造及び急性間欠性ポルフィリン症（ＡＩＰ）及び他のポルフィリン症の患者を処置するための新規な治療方法
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
CA2429210A1 (en) 2000-11-15 2002-05-23 Jason C. Goodrick Expression system for recombinant proteins
WO2002099092A2 (en) * 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human lysosomal alpha-mannosidase
AU2002317700A1 (en) * 2001-06-07 2002-12-16 Hemebiotech A/S Production of recombinant human arylsulfatase a
EP1402014A1 (en) 2001-06-29 2004-03-31 Hemebiotech A/S A process for purification of recombinant porphobilinogen deaminase
US7232670B2 (en) * 2001-09-28 2007-06-19 St. Jude Children's Research Hospital Targeting proteins to cells expressing mannose receptors via expression in insect cells
WO2003057179A2 (en) 2002-01-11 2003-07-17 Biomarin Pharmaceutical, Inc. Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2003066669A2 (en) * 2002-02-04 2003-08-14 Millipore Corporation Process for removing protein aggregates and virus from a protein solution
CH694697A5 (de) 2004-01-29 2005-06-15 Koelbl Engineering Und Consult Gummimehl-enthaltende Elastomerlegierungen.
EP1713904B1 (en) * 2004-01-30 2016-06-29 Shire Pharmaceuticals Ireland Limited Production and purification of recombinant arylsulfatase a
WO2005094874A1 (en) 2004-04-01 2005-10-13 Zymenex A/S Medical use of alpha-mannosidase
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
HUE042402T2 (hu) * 2006-04-04 2019-06-28 Chiesi Farm Spa Eljárás polipeptid töményítésére

Also Published As

Publication number Publication date
US20090246187A1 (en) 2009-10-01
US20180289777A1 (en) 2018-10-11
AU2008229659B2 (en) 2013-01-31
JP2014051503A (ja) 2014-03-20
BRPI0709737A2 (pt) 2011-07-26
IL194267A0 (en) 2011-08-01
ZA200809540B (en) 2019-09-25
ES2744499T3 (es) 2020-02-25
NO20082510L (no) 2008-10-31
KR101504969B1 (ko) 2015-03-24
JP5878152B2 (ja) 2016-03-08
JP2009532394A (ja) 2009-09-10
EP2631242B1 (en) 2022-08-03
KR20150103339A (ko) 2015-09-09
JP2014058521A (ja) 2014-04-03
HUE042402T2 (hu) 2019-06-28
AU2008229659A1 (en) 2008-10-23
IL241654A0 (en) 2015-11-30
JP2013236633A (ja) 2013-11-28
US20120076767A1 (en) 2012-03-29
JP5384232B2 (ja) 2014-01-08
EP2004672A2 (en) 2008-12-24
IL241654B (en) 2019-02-28
EP2100898A1 (en) 2009-09-16
IL235982A0 (en) 2015-01-29
AU2007234195A1 (en) 2007-10-11
CA2632528C (en) 2022-07-12
EP2100898B1 (en) 2019-06-19
NO20211305A1 (no) 2008-10-31
NZ607595A (en) 2014-10-31
US9713634B2 (en) 2017-07-25
PL2100898T3 (pl) 2019-11-29
EP2631242A2 (en) 2013-08-28
SI2628746T1 (sl) 2019-04-30
NO20084776L (no) 2008-10-31
NZ597548A (en) 2013-08-30
JP2009273469A (ja) 2009-11-26
IL194267A (en) 2015-10-29
DK2628746T3 (en) 2019-04-01
US20170202927A1 (en) 2017-07-20
EP2004672B1 (en) 2015-08-19
CN105233276A (zh) 2016-01-13
EP2628746B1 (en) 2019-01-09
NZ623123A (en) 2015-04-24
NZ571610A (en) 2011-07-29
WO2007112757A3 (en) 2008-02-28
NZ582045A (en) 2011-07-29
PT2628746T (pt) 2019-04-23
KR20090018894A (ko) 2009-02-24
EP2631242A3 (en) 2013-10-02
MX2008012748A (es) 2009-01-07
US8809055B2 (en) 2014-08-19
NZ568728A (en) 2011-09-30
IL211905A0 (en) 2011-05-31
CA2632528A1 (en) 2007-10-11
US20140314735A1 (en) 2014-10-23
NO346368B1 (no) 2022-06-27
JP2016104000A (ja) 2016-06-09
US20160193304A1 (en) 2016-07-07
NZ588903A (en) 2012-08-31
ES2713488T3 (es) 2019-05-22
AU2007234195B2 (en) 2013-02-07
PL2631242T3 (pl) 2023-03-20
ZA200805346B (en) 2018-11-28
PL2628746T3 (pl) 2019-07-31
CA2882501A1 (en) 2007-10-11
EP2628746A2 (en) 2013-08-21
NO347673B1 (no) 2024-02-19
EP2628746A3 (en) 2014-03-19
WO2007112757A2 (en) 2007-10-11
CA2882501C (en) 2021-09-07
ES2928096T3 (es) 2022-11-15
CA2644642A1 (en) 2007-10-11
KR20140057678A (ko) 2014-05-13

Similar Documents

Publication Publication Date Title
CA2644642C (en) A process for concentration of a polypeptide
US8343487B2 (en) Large-scale production of soluble hyaluronidase
HK1188604A (en) A process for the concentration of a polypeptide
HK1189007A (en) A process for concentration of a polypeptide
HK1188604B (en) A process for the concentration of a polypeptide
HK1189007B (en) A process for concentration of a polypeptide
HK1219671A (en) A process for concentration of a polypeptide
HK1219671A1 (en) A process for concentration of a polypeptide
HK40069752A (en) Large-scale production of soluble hyaluronidase

Legal Events

Date Code Title Description
EEER Examination request
H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241004

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20241115